SBIR/STTR Research Award
Liquid Biopsy for Comprehensive Genetic Profiling in Cancer
Award amount
$240,537Program and phase
SBIR · Phase IAward year
2015Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- LARIAT BIOSCIENCES, INC.
- Proposal award date
- 2015-04-08
- Contract end date
- 2016-09-30
- UEI
- Not reported
- Solicitation number
- PA14-071
- Topic code
- 102
Research abstract
DESCRIPTION provided by applicant Circulating cell free DNA in the bloodstream holds the promise of non invasive andquot liquid biopsiesandquot for cancer diagnostics Mutations that drive the growth and spread of tumors are present and detectable within this genetic pool despite being outnumbered by vast amounts of wild type DNA However there are no single genetic biomarkers of cancer and so to be of practical use many possible mutations must be screened simultaneously Current techniques lose the high sensitivity required for this needle in a haystack search once multiple mutations are targeted Lariat Biosciences is developing new technologies that break this trade off between sensitivity and breadth providing for the first tim the complete tools necessary to mine the bloodstream for clinically actionable signs of cancer The Lariat technology pairs the exquisite sensitivity of emulsion digital PCR capable of mutant quantitation at mutant to wild type ratios of to with the ability to isolate and deepl characterize the detected mutant DNA afterwards With orthogonal methods of DNA identification the false positives that undermine the multiplexed sensitivity of current technique are eliminated Lariatandapos s initial product offering will be a comprehensive genetic screen for the common mutations in EGFR and KRAS a nine plex assay that will be useful for predicting patient response to tyrosine kinase inhibitor drugs and for monitoring emerging resistance to therapy
PUBLIC HEALTH RELEVANCE Circulating cell free DNA in the bloodstream holds the promise of noninvasive andquot liquid biopsiesandquot for cancer diagnostics Mutations that drive the growth and spread of tumors are present and detectable within this genetic pool despite being outnumbered by vast amounts of healthy wild type DNA Lariat Biosciences is developing new technologies that provide for the first time the complete tools necessary to mine the bloodstream for clinically actionable signs of cancer
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- MiREA, a mHealth intervention to Reduce Health Disparities by Improving Equitable Access to Mandated College Students with Problematic Alcohol and Marijuana Use
- Modex, a cloud-based, centralized health economic model marketplace to reduce costs and enhance equity in cancer
- Precision screening in self-collected samples to reduce cervical cancer disparities among Latinas
- Allogeneic cell and gene therapy for neuroendocrine tumors
- Nanoparticle formulation of Mediator kinase inhibitor for the treatment of peritoneal ovarian cancer